Renal cell cancer is best diagnosed early and treated by complete surgical excision. There is currently no standard effective drug therapy for advanced or metastatic renal cell cancer. Chemotherapy is ineffective, and immunotherapy has only modest activity and an uncertain effect on survival. Advances in the understanding of the biology of renal cell cancer have identified tumour angiogenesis as a target for drug therapy. New therapies have therefore emerged aimed at vascular endothelial growth factor and other growth factors mediating angiogenesis. These include bevacizumab, an antibody against vascular endothelial growth factor, and the oral drugs sunitinib and sorafenib.
Introduction
In Australia, renal cell cancer is the eighth most common cancer in males and the ninth in females. In 2001 there were 2458 new cases (2.8% of all new cancers). The peak incidence occurs between 50 and 70 years. Renal cell cancers arising from the kidney epithelium account for 90-95% of all primary renal cell cancers and clear cell is the most common histology (75%). 1 While patients may classically present with local symptoms and signs (flank pain, haematuria, abdominal mass), renal cell cancer is increasingly being diagnosed by the coincidental finding of a renal mass on imaging performed for other reasons. Despite this fortuitous presentation, 25-30% of patients will have advanced or metastatic disease. 1 Common metastatic sites include lung, soft tissue, bone, liver and central nervous system. Manifestations of advanced disease include fatigue (often with anaemia), fever, weight loss and hypercalcaemia.
Renal cell cancer is generally a very vascular tumour which is insensitive to chemotherapy and only modestly sensitive to immunotherapy. The best outcome for patients is with complete excision of localised disease. Some patients with limited metastatic disease may also benefit from surgical removal of metastases. About one in three patients will relapse following curative nephrectomy 1 , hence the need for an effective systemic therapy remains.
Diagnosis and staging
The standard minimum evaluation of patients with a suspected renal cell tumour is a CT scan of abdomen and pelvis, a chest X-ray and urine analysis. A CT scan of the chest is more sensitive for small metastases. 
Adjuvant therapy
The use of adjuvant systemic therapy following radical curative nephrectomy does not improve survival. 1 In selected patients with metastatic disease and good performance status at diagnosis, radical nephrectomy followed by interferon alfa may improve survival when compared with interferon alfa alone. 2 
Systemic therapy of advanced or metastatic disease

Biologic advances in renal cancer and angiogenesis
The greatest recent developments in renal cell cancer have Recently, the genetics underlying sporadic (non-hereditary) renal cell cancer have been shown to be similar with deletion of the VHL gene allele being found in 84-98% of patients with sporadic renal tumours. 1, 4 New treatments are focusing on gene products in the angiogenesis pathway. These include VEGF, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and transforming growth factor alpha (TGF-α). 1,3,4 VEGF exerts its biologic effect through interaction with transmembrane tyrosine kinase receptors found on the cell surface (VEGFR-1 to -4, with VEGFR-2 being most important for angiogenesis). 5 These angiogenic proteins are the targets of several drugs.
Bevacizumab
This humanised VEGF neutralising monoclonal antibody was the first of the anti-angiogenic drugs to show efficacy in renal cell cancer. 4, 6 In a randomised, double-blind, phase II study 
Tyrosine kinase inhibitors
In almost all cancers, overexpression of the epidermal growth factor receptor (EGFR) has been shown to correlate with a poorer prognosis and a more malignant phenotype. Erlotinib is a small molecule which inhibits the tyrosine kinase associated with EGFR. As 80-90% of patients with renal cell cancer have EGFR overexpression, trials of erlotinib with bevacizumab are in progress. Erlotinib's main adverse reactions are an acneiform skin rash and diarrhoea. 
Self-test questions
The following statements are either true or false (answers on page 171) 1. Only 2-3% of patients with asymptomatic renal cell cancer have metastatic disease.
2. Adjuvant chemotherapy of renal cell cancer improves the survival of patients after radical curative nephrectomy.
Medicinal mishap Brand confusion with digoxin Prepared by John Balassa, General practitioner, Marrickville, New South Wales
Case
A 74-year-old retired man attended our surgery with a five-day history of upset stomach, nausea, an aversion to food, but no diarrhoea. He blamed some takeaway chicken for his problem.
His past history included valvular heart disease (mitral and aortic), myocardial infarction, chronic atrial fibrillation and partial thyroidectomy. The patient's usual medications were:
■ Lanoxin PG (digoxin 62.5 microgram) three times a day
On examination the physical findings were non-specific. The patient was given a proton pump inhibitor.
The patient returned 12 days later as he was still unwell. His pulse rate was 38 and irregular. He was having visual problems and he described blurred vision with honey coloured 'lakes' in his visual field, surrounded by yellow beads and dragonfly wing coloured areas.
Xanthopsia can be a sign of digoxin toxicity so his serum digoxin was checked. It was 6.2 nanomol/L which is a toxic concentration (therapeutic range 0.6-2.6 nanomol/L). tablets. It is therefore important to explain to patients when there is going to be a change in their brand of medication. They need to understand why the substitution is being made and that they are not being given an additional medicine.
The different brands of digoxin are marketed by different companies, however these companies seem to belong to the same corporation. The need for different brands therefore appears to be unnecessary.
